Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, PK, and Food Effect of D-2570 in Healthy Subjects
NCT07275775Phase 1Completed
- Sponsor
- InventisBio
- Start
- Aug 2024
- Primary completion
- Jun 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of D-2570 in psoriasis, ulcerative colitis (UC) and systemic lupus erythematosus (SLE) (5 arms), sponsored by InventisBio. Primary endpoints: Incidence of adverse events, Vital signs and 2 more. Started Aug 2024; status: completed.
02
Drugs
D-2570
03
Conditions
psoriasisulcerative colitis (UC)systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NCT07275775.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07275775.